Clinical Trials Logo

Autism Spectrum Disorder (ASD) clinical trials

View clinical trials related to Autism Spectrum Disorder (ASD).

Filter by:

NCT ID: NCT01248130 Terminated - Clinical trials for Autism Spectrum Disorder (ASD)

Omega-3 Fatty Acids Monotherapy in Children and Adolescents With Autism Spectrum Disorders

Start date: November 2009
Phase: Phase 2
Study type: Interventional

The primary aim of this study is to examine the efficacy and tolerability of short-term omega-3 fatty acids monotherapy in youth with Autism Spectrum Disorders (ASD). The investigators hypothesize that Omega-3 fatty acids will be efficacious in improving the core and associated features of ASD in youth, and that Omega-3 fatty acids monotherapy will be safe and well tolerated by youth with ASD. The secondary aim of this study is to examine the neuropsychological effect of Omega-3 fatty acids monotherapy in youth with ASD. The investigators hypothesize that omega-3 fatty acids will be efficacious in improving cognitive functions in youth with ASD.

NCT ID: NCT00614198 Completed - Autism Clinical Trials

ScanBrit Dietary Intervention in Autism

ScanBrit
Start date: April 2006
Phase: Phase 2
Study type: Interventional

A growing body of research indicates that dietary intervention excluding foods containing the proteins, gluten and casein, from the diet of children diagnosed with an autism spectrum disorder (ASD) may have a positive effect on behaviour and developmental outcome. In this single-blind, randomised-controlled, matched-pair adaptive trial, we introduced a gluten- and casein-free (GFCF) diet to a group of pre-pubescent children diagnosed with ASD concurrently with an abnormal urinary profile. Following random allocation to a diet or non- diet group, stage 1 of the study saw an intervention group follow the GFCF diet for eight months initially - progressing to 12 months if required. A non-diet control group continued with a normal diet. Assuming significant changes for the dietary group on the various outcome measures of behaviour and development, stage 2 of the study saw both groups assigned to GFCF dietary intervention for a further 12 months when outcome measures were again assessed at study end.